-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 H97pi6BSS9QBwa7q/hwFPUbDCKC6JbCFMvId/y0bSBDn6COGLug2rdH3iY/NwBjy
 dp8l3eBIjfV0F2qCmtmY4g==

<SEC-DOCUMENT>0001157523-10-003636.txt : 20100609
<SEC-HEADER>0001157523-10-003636.hdr.sgml : 20100609
<ACCEPTANCE-DATETIME>20100609152159
ACCESSION NUMBER:		0001157523-10-003636
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20100603
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
FILED AS OF DATE:		20100609
DATE AS OF CHANGE:		20100609

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANIKA THERAPEUTICS INC
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				043145961
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14027
		FILM NUMBER:		10887124

	BUSINESS ADDRESS:	
		STREET 1:		236 WEST CUMMINGS PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
		BUSINESS PHONE:		6179326616

	MAIL ADDRESS:	
		STREET 1:		236 WEST CUMMINGS PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a6322009.htm
<DESCRIPTION>ANIKA THERAPEUTICS, INC.
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2010 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 10pt; font-family: Times New Roman">
    <hr style="text-align: center; height: 2.5 pt; color: #000000; width: 100%">


    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 16pt"><b>UNITED
      STATES</b></font><b><font style="font-family: Times New Roman; font-size: 16pt"><br style="font-size: 16pt; font-family: Times New Roman"></font><font style="font-family: Times New Roman; font-size: 16pt">SECURITIES
      AND EXCHANGE COMMISSION</font></b><br><font style="font-size: 10pt"><b>WASHINGTON,
      D.C. 20549</b></font>
    </p>
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 16pt"><b>FORM 8-K</b></font>
    </p>
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt">CURRENT REPORT</font><font style="font-size: 12pt"><br style="font-size: 12pt"></font><font style="font-size: 12pt">Pursuant
      to Section 13 or 15(D) of the Securities Exchange Act of 1934</font>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt">Date of
      Report (Date of earliest event reported): June 3, 2010</font>
    </p>
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <font style="font-size: 16pt"><b>Anika Therapeutics, Inc.</b></font><br>(Exact
      name of registrant as specified in its charter)
    </p>
    <p>

    </p>
    <div style="text-align:left">
    <table cellspacing="0" style="font-size: 10pt; font-family: Times New Roman; margin-bottom: 10.0px; width: 100%">
      <tr>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; width: 33%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Massachusetts</b>
          </p>
        </td>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; width: 34%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>000-21326</b>
          </p>
        </td>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; width: 33%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>04-3145961</b>
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: center; padding-left: 0.0px; width: 33%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (State or other jurisdiction<br>of incorporation)
          </p>
        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px; width: 34%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (Commission File<br>Number)
          </p>
        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px; width: 33%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (IRS Employer<br>Identification No.)
          </p>
        </td>
      </tr>
    </table>
    </div>
    <div style="text-align:left">
    <table cellspacing="0" style="font-size: 10pt; font-family: Times New Roman; margin-bottom: 10.0px; width: 100%">
      <tr>
        <td valign="top" style="text-align: center; padding-left: 0.0px; width: 60%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>32 Wiggins Avenue</b>
          </p>
        </td>
        <td style="width: 10%">
          &#160;
        </td>
        <td style="width: 30%">

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: center; padding-left: 0.0px; width: 60%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Bedford, MA</b>
          </p>
        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px; width: 10%">

        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; width: 30%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>01730</b>
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: center; padding-left: 0.0px; width: 60%">
          (Address of principal executive offices)
        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px; width: 10%">

        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px; width: 30%">
          (Zip code)
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">
      <font style="font-size: 10pt">Registrant&#8217;s telephone number, including
      area code:&#160;&#160;</font><font style="font-size: 10pt"><b>(781)
      457-9000</b></font>
    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt"><b>N/A</b></font><font style="font-size: 10pt"><br style="font-size: 10pt"></font><font style="font-size: 10pt">(Former
      name or former address, if changed since last report)</font>
    </p>
    <p style="text-align: center">

    </p>
    <p>
      <font style="font-family: Times New Roman; font-size: 10pt">Check the
      appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligation of the registrant under any
      of the following provisions:</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font><br><font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font><br><font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font><br><font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font>
    </p>
    <p>

    </p>
    <div style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; margin-bottom: 10pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <div style="text-align:left">
    <table cellspacing="0" style="font-size: 10pt; font-family: Times New Roman; margin-bottom: 10.0px; width: 100%">
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 10%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Item 5.07</b>
          </p>
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 2%">
          &#160;
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 88%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Submission of Matters to a Vote of Security Holders.</b>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="font-size: 10pt; text-indent: 30.0px; font-family: Times New Roman">
      Anika Therapeutics, Inc. (the &#8220;Company&#8221;) held its Annual Meeting of
      Stockholders on June 3, 2010.&#160;&#160;Proxies were solicited pursuant to the
      Company&#8217;s proxy statement filed on April 22, 2010 with the Securities
      and Exchange Commission under Section 14(a) of the Securities Exchange
      Act of 1934. There was no solicitation in opposition to the Company&#8217;s
      solicitation.&#160;&#160;At the meeting, holders of the Company&#8217;s common stock
      were asked (1) to elect two (2) Class II directors, each to serve until
      the 2013 Annual Meeting of Stockholders and until their respective
      successors are duly elected and qualified, and (2) to ratify the
      appointment of PricewaterhouseCoopers LLP as the Company&#8217;s independent
      registered public accounting firm for the 2010 fiscal year.&#160;&#160;Each share
      of the Company&#8217;s common stock was entitled to one vote with respect to
      matters submitted to a vote of the Company&#8217;s stockholders, and the
      voting results reported below are final.
    </p>
    <p>

    </p>
    <p>
      <u><b>PROPOSAL 1</b></u>
    </p>
    <p style="font-size: 10pt; text-indent: 30.0px; font-family: Times New Roman">
      Each of the Company&#8217;s nominees for director as listed in the proxy
      statement was re-elected as shown in the table below. &#160;There were no
      votes against or votes abstained with respect to any director
      nominee.&#160;&#160;There were 5,442,170 broker non-votes with respect to Proposal
      1.
    </p>
    <div style="text-align:left">
    <table cellspacing="0" style="font-size: 10pt; font-family: Times New Roman; margin-bottom: 10.0px; width: 100%">
      <tr>
        <td valign="bottom" style="text-align: left; padding-left: 0.0px; border-bottom: solid black 1.0pt; width: 33%">
          <b>Nominee</b>
        </td>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; border-bottom: solid black 1.0pt; width: 34%">
          <b>Votes &#8220;For&#8221;</b>
        </td>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; border-bottom: solid black 1.0pt; width: 33%">
          <b>Votes Withheld</b>
        </td>
      </tr>
      <tr>
        <td valign="bottom" style="text-align: left; padding-left: 0.0px; width: 33%">
          Raymond J. Land
        </td>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; width: 34%">
          6,117,973
        </td>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; width: 33%">
          659,705
        </td>
      </tr>
      <tr>
        <td valign="bottom" style="text-align: left; padding-left: 0.0px; width: 33%">
          John C. Moran
        </td>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; width: 34%">
          6,117,973
        </td>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; width: 33%">
          659,705
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <p>
      <u><b>PROPOSAL 2</b></u>
    </p>
    <p style="font-size: 10pt; text-indent: 30.0px; font-family: Times New Roman">
      &#160;Stockholders also ratified the appointment of PricewaterhouseCoopers
      LLP as the Company&#8217;s independent registered public accounting firm for
      the 2010 fiscal year as shown below.&#160; There were no broker non-votes and
      no votes withheld with respect to Proposal 2.
    </p>
    <div style="text-align:left">
    <table cellspacing="0" style="font-size: 10pt; font-family: Times New Roman; margin-bottom: 10.0px; width: 100%">
      <tr>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; border-bottom: solid black 1.0pt; width: 33%">
          <b>Votes &#8220;For&#8221;</b>
        </td>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; border-bottom: solid black 1.0pt; width: 34%">
          <b>Votes Against</b>
        </td>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; border-bottom: solid black 1.0pt; width: 33%">
          <b>Votes Abstained</b>
        </td>
      </tr>
      <tr>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; width: 33%">
          11,648,635
        </td>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; width: 34%">
          558,847
        </td>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; width: 33%">
          12,366
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; margin-bottom: 10pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <u><font style="font-family: Times New Roman; font-size: 10pt">SIGNATURES</font></u><br>
    </p>
    <p style="font-size: 10pt; text-indent: 30.0px; font-family: Times New Roman">
      Pursuant to the requirements of the Securities Exchange Act of 1934, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, hereunto duly authorized.
    </p>
    <div style="text-align:left">
    <table cellspacing="0" style="font-size: 10pt; font-family: Times New Roman; margin-bottom: 10.0px; width: 100%">
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 5%">
          &#160;
        </td>
        <td style="width: 43%">

        </td>
        <td valign="top" colspan="2" style="text-align: left; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Anika Therapeutics, Inc.
          </p>
        </td>
        <td style="width: 15%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 43%">

        </td>
        <td colspan="2">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 15%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 43%">

        </td>
        <td valign="top" colspan="2" style="text-align: left; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 15%">

        </td>
      </tr>
      <tr>
        <td valign="top" colspan="2" style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Date: June 9, 2010
          </p>
        </td>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px; width: 7%">
          By:
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; border-bottom: solid black 1.0pt; width: 30%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            /s/ Kevin W. Quinlan
          </p>
        </td>
        <td style="width: 15%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 43%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 7%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Name:
          </p>
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 30%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Kevin W. Quinlan
          </p>
        </td>
        <td style="width: 15%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 43%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 7%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Title:
          </p>
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 30%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Chief Financial Officer
          </p>
        </td>
        <td style="width: 15%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 43%">

        </td>
        <td style="width: 7%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 30%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 15%">

        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
